期刊文献+

治疗前乳酸脱氢酶、神经元烯醇化酶水平与小细胞肺癌预后的相关性 被引量:8

暂未订购
导出
摘要 目的分析小细胞肺癌患者治疗前神经元烯醇化酶(NSE)、乳酸脱氢酶(LDH)水平与其预后的关联性。方法回顾性调查该院2006年10月至2012年12月住院的105例小细胞肺癌患者的病历资料,记录病人治疗前临床特征和NSE、LDH水平,分析其对总生存的影响。结果治疗前分期、PS评分、NSE水平、LDH水平与小细胞肺癌总生存显著相关(P<0.05)。NSE,LDH与总生存的关联效应仅存在于局限期。结论NSE和LDH是评估小细胞肺癌预后的理想生物标记物,尤其对于局限期病变。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2013年第10期2272-2274,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献1

二级参考文献19

  • 1Fraser RS, Muller NL, Colman N, et al. Pulmonary carcinoma. In: Fraser RS, Muller NL, Colman N, Pare PD, eds. In diagnosis of diseases of the chest, 4th ed. Vol. 2. Philadelphia: Saunders, 1999. 1070-1228.
  • 2Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 49(2): 119-133.
  • 3Bremnes RM, Sundstrom S, Aaseb U, et al. Norweigian Lung Cancer Study Group: The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39(3): 303-313.
  • 4Lima JE, Takayanagui OM, Garcia LV, et al. Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. BrazJ Med Biol Res, 2004, 37(1): 19-26.
  • 5Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer, 1998, 82(6): 1049-1055.
  • 6Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res, 2007, 27(4A): 1911-1915.
  • 7Van de Pol M, Twijnstra A, ten Velde GP, et al. Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma. J Neurooncol, 1994, 19(2): 149-154.
  • 8Q uoix E, Purohit A, Failer-Beau M, et aL Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30(2): 127-134.
  • 9Ebert W, Muley T, Drings P. Does the assessment of serum makers in patients with lung cancer aid i'n the clinical decision making process. Anticancer Res, 1996, 16(4B): 2161-2168.
  • 10Jorgensen LG, Osterlind K, Hansen HH, et al. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer, 1988, 58(6): 805-807.

共引文献16

同被引文献89

  • 1邵亚娟,王颖轶,孟长婷,王毓洲.小细胞肺癌77例治疗及预后分析[J].中国医学科学院学报,2010,32(4):394-397. 被引量:18
  • 2贺恒鹏,于雯婷.血清C反应蛋白与小细胞肺癌患者预后的相关性[J].中国老年学杂志,2014,34(9):2551-2552. 被引量:2
  • 3任秀红,董文川,刘平平.晚期非小细胞肺癌患者CRP与肿瘤标记物的对比分析[J].华南国防医学杂志,2005,19(5):14-16. 被引量:7
  • 4周薇,胡世莲.氨基酸支持治疗的非小细胞肺癌患者血清炎症因子水平的变化[J].中国临床保健杂志,2007,10(1):26-28. 被引量:6
  • 5宋向芹,彭新国,周玉明,等.血清CEA、CYFRA21-1、NSE检测对原发性肺癌治疗后复发的诊断价值[J].泸州医学院学报,2009,32(5):357-358.
  • 6Molina R, Auge JM, Filella X, et al. Pro-gastrln-releasing peptide (Pro-GRP) in patients with benign and malignant diseases: compari- son with CEA, SCC, CYF 21-1 and NSE in patients with lung cancer [J]. Anticancer Res, 2005, 25(3A) : 1773-1778.
  • 7Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Canc- er Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming ( sev- enth) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2009, 4(9) :1049-1059.
  • 8Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be reevaluated? [J]. Cancer, 2010, 116(5) : 1350-1357.
  • 9Planchard D,Le Pechoux C.Small cell lung cancer:new clinical recommendations and current status of biomarker assessment[J].Eur J Cancer,2011,47(Suppl 3):S272-283.
  • 10Hurwitz JL,Mc Coy F,Scullin P,et al.New advances in the second-line treatment of small cell lung cancer.Oncologist[J].2009,14(10):986-994.

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部